CN Patent

CN117402059A — 包含15-氧代-epa或15-氧代-dgla的组合物及其制备和使用方法

Assigned to DS Biopharma Ltd · Expires 2024-01-16 · 2y expired

What this patent protects

本公开提供15‑氧代‑EPA和15‑氧代‑DGLA、包含15‑氧代‑EPA和/或15‑氧代‑DGLA的组合物以及通过施用15‑氧代‑EPA和/或15‑氧代‑DGLA来在有此需要的受试者中治疗和/或预防纤维化、皮肤病症、炎症、肾病或肾功能障碍的方法。

USPTO Abstract

本公开提供15‑氧代‑EPA和15‑氧代‑DGLA、包含15‑氧代‑EPA和/或15‑氧代‑DGLA的组合物以及通过施用15‑氧代‑EPA和/或15‑氧代‑DGLA来在有此需要的受试者中治疗和/或预防纤维化、皮肤病症、炎症、肾病或肾功能障碍的方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN117402059A
Jurisdiction
CN
Classification
—
Expires
2024-01-16
Drug substance claim
No
Drug product claim
No
Assignee
DS Biopharma Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.